New York Medical College

This phase 2 trial tests a risk-adapted treatment for children, adolescents, and young adults with relapsed or refractory ALK-positive anaplastic large cell lymphoma. Participants receive nivolumab (an immunotherapy) combined with chemotherapy drugs like vinblastine or brentuxima…

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This early-phase trial tests a four-drug combination—vorinostat plus three chemotherapy drugs—in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vo…

This study tests whether increasing the dose of defibrotide can safely help patients with a serious liver condition called SOS/VOD that occurs after a stem cell transplant. The condition can damage the kidneys and lungs and often does not improve with standard defibrotide doses. …

This study tests whether specially grown immune cells (BK-specific cytotoxic T-cells) from a related donor can safely lower BK virus levels in children, teens, and young adults. Participants have BK infections that did not get better with standard treatment, often after a stem ce…

This early-phase trial tests whether adding daratumumab (an immunotherapy drug) after a stem cell transplant can safely help control high-risk T-cell acute lymphoblastic leukemia or lymphoma in children, teens, and young adults up to age 39. About 30 participants will receive the…

This study tests a stronger, more frequent dosing schedule of the drug rituximab in children and young adults (ages 1 to 21) with newly diagnosed immune thrombocytopenic purpura (ITP) who are at high risk for severe bleeding. The goal is to see if this approach can safely improve…

This study tests whether special immune cells (called T cells) taken from a family member who already recovered from COVID-19 can safely treat mild to moderate COVID-19 in hospitalized adults. The cells are designed to attack the virus. The trial involves 50 participants and aims…

This study tests whether adding special immune cells from the mother to standard antiviral medicine can safely and more effectively treat moderate to severe CMV infection in newborns. Babies up to 21 days old with confirmed CMV disease may join. All receive antiviral drugs, and s…